Search Results 51-60 of 21244 for anti-TNF drugs

1. Adalimumab-Atto (Subcutaneous Route) Before Using - Mayo Clinic

   Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

2. Sacroiliitis - Diagnosis and treatment - Mayo Clinic

   Tumor necrosis factor (TNF) inhibitors include etanercept (Enbrel), adalimumab (Humira), infliximab (Remicade) and golimumab (Simponi). Both types of ...

3. Adalimumab-Fkjp (Subcutaneous Route) Before Using - Mayo Clinic

   Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

4. Adalimumab-Aqvh (Subcutaneous Route) Precautions - Mayo Clinic

   Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines ...

5. Etanercept-Szzs (Subcutaneous Route) Before Using - Mayo Clinic

   Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

6. Etanercept-Szzs (Subcutaneous Route) Side Effects - Mayo Clinic

   Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

7. A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants with Moderately to Severely Active Crohn's Disease (CD) - Mayo Clinic

   Anti-TNF Therapy. Inadequate primary non-response: Did not respond (as ... Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs). Prophylactic ...

8. Rheumatoid Arthritis Clinical Trials - Mayo Clinic Research

   ... treatment with modifying antirheumatic drugs (DMARDs) or anti-TNF alpha agents. Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis ...

9. A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy - Mayo Clinic

   * Must have failed anti-TNF treatment for HS. * To be eligible for the Sub-study, participants must be naïve to biologic therapy for treatment of HS.

10. Weekend Wellness: Ankylosing spondylitis symptom changes hard to predict - Mayo Clinic News Network

    When these symptoms are persistent, treatment usually involves medications known as TNF blockers. ... Examples of these medications include adalimumab, etanercept ...